Health related quality of life in prostate carcinoma patients: A systematic review of randomized controlled trials

Cancer

Volumn 97, Issue 2, 2003, Pages 377-388

  Efficace, Fabio ^a   Bottomley, Andrew ^a   Van Andel, George ^b  

^a EORTC DATA CENTER   (Belgium)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Prostate carcinoma; Quality of life; Randomized controlled trials; Systematic review

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CORTICOSTEROID; CYPROTERONE ACETATE; EPIRUBICIN; FLUTAMIDE; GOSERELIN; HYDROCORTISONE; LIAROZOLE; MEGESTROL ACETATE; MITOXANTRONE; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; STRONTIUM 89; SURAMIN; TEGAFUR; UFT; URACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BEAM THERAPY; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPNEA; EMOTION; FATIGUE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; METASTASIS; NAUSEA; ORCHIECTOMY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE DISEASE; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 0037439443     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11065     Document Type: Article

References (68)

1. Kiebert GM. Quality of life as an outcome measure in cancer clinical trials. Eur Urol. 1997;31(Suppl 1):56-64.
2. Moinpour CM. Measuring quality of life: an emerging science. Semin Oncol. 1994;21(Suppl 10):48-60.
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
4. Feld R. Endpoints in cancer clinical trials: is there a need for measuring quality of life? Support Care Cancer. 1995;3:23-27.
5. Kong SX, Ghandi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother. 1997;31:830-836.
6. Velikova G, Stark D, Selby P. Quality of life instruments in oncology. Eur J Cancer. 1999;35:1571-1580.
7. Schumacher M, Olschewski M, Schulgen G. Assessment of quality of life in clinical trials. Stat Med. 1991;10:1915-1930.
8. Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ. 1998;317:1191-1194.
9. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42-46.
10. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
11. Yarbro CH, Ferrans CE. Quality of life of patients with prostate cancer treated with surgery or radiation therapy. Oncol Nurs Forum. 1998;25:685-693.
12. Sommers SD, Ramsey SD. A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics. 1999;16:127-140.
13. Schellhammer P, Cockett A, Boccon-Gibod L, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997;49(Suppl 4A):27-38.
14. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer. 1998;57:109-112.
15. Titzer ML, Fisch M, Kristeller JL, et al. Clinicians' assessment of quality of life (QOL) in outpatients with advanced cancer: how accurate is our prediction? A Hoosier Oncology Group Study [abstract]. Proc Am Soc Clin Oncol. 2001;20:1532.
16. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol. 1992;45:743-760.
17. Fayers P, Machin D. Quality of life. Assessment, analysis and interpretation. Chichester, UK: John Wiley & Sons, 2000.
18. Stephens RJ, Hopwood P, Girling DJ, et al. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res. 1997;6:225-236.
19. Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians. Qual Life Res. 2000;9:1041-1052.
20. Moher D, Jones A, Lepage L. CONSORT Group. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before- and-after evaluation. JAMA. 2001;285:1992-1995.
21. Staquet M, Berzon R, Osoba D, et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5:496-502.
22. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health related quality of life - a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209-238.
23. Bottomley A, Thomas R, van Stenn K, et al. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol. 2002;3:145-153.
24. Efficace F, Bottomley A. Health-related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer. 2002;38:1824-1831.
25. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
26. Chodak G, Sharifi R, Kasimis B, et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology. 1995;46:849-855.
27. Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology. 1995;45:745-752.
28. Tannock IF, Osoba D, Steckler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
29. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1998;90:1537-1544.
30. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
31. Duncan GG, Philips N, Pickles T. Report on the quality of life analysis from the Phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer. Eur J Cancer. 2000;36:759-765.
32. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18:1440-1450.
33. Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000;88:825-834.
34. Thrasher JB, Deeths J, Bennett C, et al. Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000;4:259-263.
35. Kaisary AV, Tyrrell CJ, Beacock C, et al. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur Urol. 1995;28:215-222.
36. Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 mg monotherapy vs. orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol. 1996;30:93-98.
37. da Silva FC, Fossa SD, Aaronson NK, et al. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer. 1996;32:72-77.
38. Pummer K, Lehnert M, Stettner H, et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol. 1997;32(Suppl 3):81-85.
39. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999;17:2027-2038.
40. Fossa SD, Curran D, Aaronson NK, et al. Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchidectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893. Eur Urol. 2000;37:541-551.
41. Johansson JE, Wersall P, Brandberg Y, et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer - a randomized study. Scand J Urol Nephrol. 2001;35:288-294.
42. Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer. 2001;92:3111-3119.
43. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19:62-71.
44. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447-456.
45. Debruyne FJ, Murray R, Fradet Y, et al. Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 1998;52:72-81.
46. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology. 1998;51:389-396.
47. Akakura K, Isaka S, Akimoto S, et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology. 1999;54:313-318.
48. Homma Y, Akaza H, Okada K, et al. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group. Int J Urol. 1999;6:229-237
49. Kuriyama M, Takahashi Y, Sahashi M, et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol. 2001;31:18-24.
50. Fairclough DL. Design and analysis of quality of life studies in clinical trials. New York: Chapman & Hall/CRC, 2002.
51. Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res. 1995;4:207-220.
52. Osoba D, Tannock IF, Ernst DS, et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654-1663.
53. Huth EJ. Irresponsible authorship and wasteful publication. Ann Intern Med. 1986;104:257-259.
54. Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet. 1996;347:1024-1026.
55. Tramer MR, Reynolds DJ, Moore RA, et al. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315:635-640.
56. Pummer K. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. Semin Oncol. 1991;18(Suppl 6):26-28.
57. Soloway MS, Schellhammer P, Sharifi R, et al. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29(Suppl 2):105-109.
58. Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993;42:119-129.
59. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.
60. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993;20(Suppl 2):38-43.
61. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 1996;47(Suppl 1A):38-43.
62. Tyrrell CJ. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. Eur Urol. 1994;26(Suppl 1):15-19.
63. Schellhammer PF, Sharifi R, Block NL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996;78:2164-2169.
64. Schellhammer P, Sharifi R, Block N, et al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Urology. 1996;47(Suppl 1A):54-60.
65. Rosendahl I, Kiebert GM, Curran D, et al. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer. Prostate. 1999;38:100-109.
66. Bloomfield DJ, Krahn MD, Neogi T, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol. 1998;16:2272-2279.
67. Pickles T, Goodman GB, Fryer CJ, et al. Pion conformal radiation of prostate cancer: results of a randomized study. Int J Radiat Oncol Biol Phys. 1999;43:47-55.
68. de Reijke TM, Keuppens FI, Whelan P, et al. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol. 1999;162:1658-1664.